Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Enzon Pharmaceuticals ( (ENZN) ).
On June 20, 2025, Enzon Pharmaceuticals and Viskase Companies announced a definitive merger agreement where Viskase will merge into a wholly owned subsidiary of Enzon in an all-stock transaction. The combined entity, to be named Viskase Holdings, Inc., will trade on the OTCQX market. The merger, unanimously approved by both companies’ boards, is expected to result in Viskase stockholders owning approximately 84.1% of the new company, while Enzon stockholders will hold the remaining 15.9%. The merger aims to enhance operational capabilities and market reach, with Timothy P. Feast, the current CEO of Viskase, leading the combined company.
More about Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc. is positioned as a public company acquisition vehicle, aiming to become an acquisition platform. Viskase Companies, Inc. is a producer of non-edible cellulosic, fibrous, and plastic casings used for processed meat products, operating nine manufacturing facilities globally and serving major consumer product companies.
Average Trading Volume: 16,566
Technical Sentiment Signal: Sell
Current Market Cap: $6.01M
For an in-depth examination of ENZN stock, go to TipRanks’ Overview page.